Abstract
Cells constantly adapt to external humoral cues like cytokines and hormones, but practically most cellular behavior is under locally guided control via cell–cell interactions. Galectins (Gals) are one of the most prominent members of the group of molecules involved in this intercellular signaling. They are the family of β-galactoside specific lectins and consist of 15 different types, each with a specific function. They play crucial role in the immune system, inflammation, wound healing and carcinogenesis. In recent times, the role of Gals in the development of cardiovascular disease (CVD) has gained attention. Gals have been reported to act ambiguously by both relieving ischemia and accelerating atherosclerosis. Atherosclerosis can ultimately lead to myocardial infarction or ischemic stroke, which are both associated with Gals. There is also a role for Gals in the development of myocarditis by their influence on inflammatory processes. Moreover, Gal acts as a biomarker for the severity of myocardial ischemia and heart failure (HF). This review summarizes the association between Gals and the development and pathogenesis of CVD like atherosclerosis, stroke, myocardial infarction, and HF. A comprehensive outline of the association between Gals and more general mechanisms such as angiogenesis, arteriogenesis and atherosclerosis has also been provided. Modulation of Gal signaling holds great promise for the treatment of CVD as evident from preclinical studies.
Keywords: Angiogenesis, atherosclerosis, cardiovascular disease, galectin, therapy.
Current Vascular Pharmacology
Title:Galectins-A Potential Target for Cardiovascular Therapy
Volume: 15 Issue: 4
Author(s): Ghulam Md. Ashraf*, Asma Perveen, Syed Kashif Zaidi, Ausaf Ahmad, Shazi Shakil, Chelapram Kandy Firoz, Nasimudeen R. Jabir, Iftekhar Hassan, Taqi Ahmad Khan, Nagendra Sastry Yarla and Shams Tabrez*
Affiliation:
- King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589,Saudi Arabia
- King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589,Saudi Arabia
Keywords: Angiogenesis, atherosclerosis, cardiovascular disease, galectin, therapy.
Abstract: Cells constantly adapt to external humoral cues like cytokines and hormones, but practically most cellular behavior is under locally guided control via cell–cell interactions. Galectins (Gals) are one of the most prominent members of the group of molecules involved in this intercellular signaling. They are the family of β-galactoside specific lectins and consist of 15 different types, each with a specific function. They play crucial role in the immune system, inflammation, wound healing and carcinogenesis. In recent times, the role of Gals in the development of cardiovascular disease (CVD) has gained attention. Gals have been reported to act ambiguously by both relieving ischemia and accelerating atherosclerosis. Atherosclerosis can ultimately lead to myocardial infarction or ischemic stroke, which are both associated with Gals. There is also a role for Gals in the development of myocarditis by their influence on inflammatory processes. Moreover, Gal acts as a biomarker for the severity of myocardial ischemia and heart failure (HF). This review summarizes the association between Gals and the development and pathogenesis of CVD like atherosclerosis, stroke, myocardial infarction, and HF. A comprehensive outline of the association between Gals and more general mechanisms such as angiogenesis, arteriogenesis and atherosclerosis has also been provided. Modulation of Gal signaling holds great promise for the treatment of CVD as evident from preclinical studies.
Export Options
About this article
Cite this article as:
Md. Ashraf Ghulam *, Perveen Asma , Zaidi Kashif Syed , Ahmad Ausaf , Shakil Shazi , Firoz Kandy Chelapram , Jabir R. Nasimudeen , Hassan Iftekhar , Khan Ahmad Taqi , Yarla Sastry Nagendra and Tabrez Shams *, Galectins-A Potential Target for Cardiovascular Therapy, Current Vascular Pharmacology 2017; 15 (4) . https://dx.doi.org/10.2174/1570161115666170201113046
DOI https://dx.doi.org/10.2174/1570161115666170201113046 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Associate Editor:
Cardiovascular & Hematological Disorders-Drug Targets The Protective Role of Crocus Sativus L. (Saffron) Against Ischemia- Reperfusion Injury, Hyperlipidemia and Atherosclerosis: Nature Opposing Cardiovascular Diseases
Current Cardiology Reviews Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism A Proposal----The Renal Kallikrein-Kinin System as a Compensating System for Salt Accumulation after Excess Salt Intake
Current Hypertension Reviews Ion Channel Drug Discovery and Research: The Automated Nano-Patch- ClampO Technology
Current Drug Discovery Technologies The Potential Role of Naringin and Naringenin as Nutraceuticals Against Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets cGMP Signaling, Phosphodiesterases and Major Depressive Disorder
Current Neuropharmacology Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology Molecular Evaluation of MicroRNA-146 Gene Variability (rs2910164 C> G) and its Association with Increased Susceptibility to Coronary Artery Disease
MicroRNA Management and Outcomes of Aortic Dissection in Pregnancy with Marfan Syndrome: A Systematic Review
Current Vascular Pharmacology Optimal Oxygen Therapy in the Critically Ill Patient with Respiratory Failure
Current Respiratory Medicine Reviews Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Diagnoses of Gastrointestinal Cancers After Gastrointestinal Bleeding in Patients Receiving Clopidogrel or Warfarin
Current Drug Safety Elucidation of Pathophysiology and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review
Cardiovascular & Hematological Agents in Medicinal Chemistry The Molecular Nature and Consequences of Lipoprotein (A)s Association with Platelets
Protein & Peptide Letters Endothelial and Cardiac Dysfunction in Inflammatory Bowel Diseases: Does Treatment Modify the Inflammatory Load on Arterial and Cardiac Structure and Function?
Current Vascular Pharmacology Decreasing Arterial Aging by Controlling Blood Pressure Levels and Hypertension: A Step Forward
Current Vascular Pharmacology Computer-Aided Drug Discovery and Design Targeting Ion Channels
Current Topics in Medicinal Chemistry Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions
Current Protein & Peptide Science